Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trialJean‐Yves Blay, Margaret von Mehren, Patrick Schöffski et al.|The Lancet Oncology|2020Cited by 406
Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumoursCésar Serrano, Jonathan A. Fletcher|British Journal of Cancer|2019Cited by 165
Diagnosis and management of tropomyosin receptor kinase (TRK) fusion sarcomas: expert recommendations from the World Sarcoma NetworkGeorge D. Demetri, Jean‐Yves Blay, Cristina R. Antonescu et al.|Annals of Oncology|2020Cited by 145